Antibody Targeting of Conserved Sites of Vulnerability on the SARS-CoV-2 Spike Receptor-binding Domain

Given the continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved epitopes on the spike (S) glycoprotein have therapeutic advantages. Here, we report the crystal structure of the SARS-CoV-2 S receptor-binding domain (RBD) at 1.95 Å and describe flexibility and distinct conformations of the angiotensin-converting enzyme 2 (ACE2)-binding site. We identify a set of SARS-CoV-2-reactive monoclonal antibodies (mAbs) with broad RBD cross-reactivity including SARS-CoV-2 Omicron subvariants, SARS-CoV-1, and other sarbecoviruses and determine the crystal structures of mAb-RBD complexes with Ab246 and CR3022 mAbs targeting the class IV site, WRAIR-2134, which binds the recently designated class V epitope, and WRAIR-2123, the class I ACE2-binding site. The broad reactivity of class IV and V mAbs to conserved regions of SARS-CoV-2 VoCs and other sarbecovirus provides a framework for long-term immunotherapeutic development strategies.

Citing Articles

Contrastive Learning Enables Epitope Overlap Predictions for Targeted Antibody Discovery.

Holt C, Janke A, Amlashi P, Jamieson P, Marinov T, Georgiev I bioRxiv. 2025; .

PMID: 40060439 PMC: 11888244. DOI: 10.1101/2025.02.25.640114.

Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies.

Mazigi O, Langley D, Henry J, Burnett D, Sobti M, Walker G Proc Natl Acad Sci U S A. 2025; 122(1):e2417544121.

PMID: 39746041 PMC: 11725916. DOI: 10.1073/pnas.2417544121.

Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.

Discovery, recognized antigenic structures, and evolution of cross-serotype broadly neutralizing antibodies from porcine B-cell repertoires against foot-and-mouth disease virus.

Li F, Wu S, Lv L, Huang S, Zhang Z, Zerang Z PLoS Pathog. 2024; 20(10):e1012623.

PMID: 39405339 PMC: 11508087. DOI: 10.1371/journal.ppat.1012623.

Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.

Guerra D, Radic L, Brinkkemper M, Poniman M, van der Maas L, Torres J Hum Vaccin Immunother. 2024; 20(1):2388344.

PMID: 39165108 PMC: 11340772. DOI: 10.1080/21645515.2024.2388344.

References

Chakraborty C, Bhattacharya M, Chopra H, Islam M, Saikumar G, Dhama K . The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?. Int J Surg. 2023; 109(4):1041-1043. PMC: 10132296. DOI: 10.1097/JS9.0000000000000246. View

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

Alrubayyi A, Schuetz A, Lal K, Jongrakthaitae S, Paolino K, Ake J . A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. J Immunol Methods. 2018; 462:74-82. DOI: 10.1016/j.jim.2018.08.012. View

Wu N, Yuan M, Bangaru S, Huang D, Zhu X, Lee C . A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020; 16(12):e1009089. PMC: 7744049. DOI: 10.1371/journal.ppat.1009089. View

Ter Meulen J, van den Brink E, Poon L, Marissen W, Leung C, Cox F . Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006; 3(7):e237. PMC: 1483912. DOI: 10.1371/journal.pmed.0030237. View

Wrobel A, Benton D, Xu P, Roustan C, Martin S, Rosenthal P . SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol. 2020; 27(8):763-767. PMC: 7610980. DOI: 10.1038/s41594-020-0468-7. View

Jensen J, Sankhala R, Dussupt V, Bai H, Hajduczki A, Lal K . Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity. J Virol. 2023; 97(7):e0159622. PMC: 10373542. DOI: 10.1128/jvi.01596-22. View

Bullen G, Galson J, Hall G, Villar P, Moreels L, Ledsgaard L . Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses. Front Immunol. 2021; 12:678570. PMC: 8239432. DOI: 10.3389/fimmu.2021.678570. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

10.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

11.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

12.

Chen J, Wang R, Gilby N, Wei G . Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022; 62(2):412-422. PMC: 8751645. DOI: 10.1021/acs.jcim.1c01451. View

13.

Zhu X, Mannar D, Srivastava S, Berezuk A, Demers J, Saville J . Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol. 2021; 19(4):e3001237. PMC: 8112707. DOI: 10.1371/journal.pbio.3001237. View

14.

Wang L, Zhou T, Zhang Y, Yang E, Schramm C, Shi W . Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021; 373(6556). PMC: 9269068. DOI: 10.1126/science.abh1766. View

15.

Wang L, Shi W, Chappell J, Joyce M, Zhang Y, Kanekiyo M . Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018; 92(10). PMC: 5923077. DOI: 10.1128/JVI.02002-17. View

16.

Joyce M, King H, Elakhal-Naouar I, Ahmed A, Peachman K, Cincotta C . A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci Transl Med. 2021; 14(632):eabi5735. DOI: 10.1126/scitranslmed.abi5735. View

17.

Xiong H, Sun H, Wang S, Yuan L, Liu L, Zhu Y . The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proc Natl Acad Sci U S A. 2022; 119(34):e2204256119. PMC: 9407403. DOI: 10.1073/pnas.2204256119. View

18.

Gobeil S, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V . Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science. 2021; 373(6555). PMC: 8611377. DOI: 10.1126/science.abi6226. View

19.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

20.

Winkler E, Gilchuk P, Yu J, Bailey A, Chen R, Chong Z . Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021; 184(7):1804-1820.e16. PMC: 7879018. DOI: 10.1016/j.cell.2021.02.026. View